Saturday, November 23, 2019, Phoenix, Arizona, 12:15 PM – 1:15 PM

Consensus or Controversy? The Integration of Novel Therapies into the Interdisciplinary Management of Non-Small Cell Lung Cancer with CNS Metastases

A Satellite Symposium During the 24th Annual Meeting and Education Day of the Society for Neuro-Oncology

Location
JW Marriott Desert Ridge Resort & Spa
5350 E Marriott Drive
Phoenix, AZ 85054
Hotel Phone: (480) 293-5000

Time
11:45 AM – 12:15 PM — Registration and Lunch Buffet
12:15 PM – 1:15 PM — Educational Meeting

Meeting Room
Grand Sonoran F (Level 1)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
 
Faculty
Manmeet Ahluwalia, MD
Miller Family Endowed Chair in NeuroOncology
Associate Director and Head of Operations
Burkhardt Brain Tumor and Neuro-Oncology Center
Cleveland Clinic
Professor, Cleveland Clinic Lerner College of
Medicine of Case Western Reserve University
Cleveland, Ohio

Daniel Gomez, MD, MBA
Radiation Oncologist
Director of Thoracic Oncology
Chief of Radiation Oncology, Manhattan Service
Memorial Sloan Kettering Cancer Center
New York, New York

Gregory J Riely, MD, PhD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York


Moderator
Matthew Gubens, MD, MS
Associate Professor, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California


The Society for Neuro-Oncology has reviewed and approved this symposium as appropriate for presentation as an Industry Supported Symposium. The symposium constitutes the content and views of the sponsor and is not part of the official SNO Annual Meeting program.

For this CME symposium 4 of the world’s leading researchers with expertise in radiation, neuro-oncology and the management of lung cancer will serve as the faculty, one of whom will moderate the program. Prior to the event, the invited faculty and several other investigators will complete a survey centered on challenging questions and controversial scenarios specific to the management of non-small cell lung cancer and brain metastases. The responses from all experts will be summarized to illustrate the group’s collective perspectives. The program will be divided into 3 distinct modules, each featuring a discussion of select survey results and a faculty member-led review of related clinical research. To make the program more interactive, preregistrants will be invited to complete an online survey featuring many of the same questions posed to the investigators, and results from both cohorts will be juxtaposed to highlight any knowledge or practice gaps.

A detailed agenda will be made available in the coming weeks.

Target Audience
This activity is intended for neuro-oncologists, neurosurgeons, medical oncologists and other neuro-oncology practitioners involved in the treatment of lung cancer and CNS metastases.

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Discern the overall incidence of central nervous system (CNS) involvement among patients with non-small cell lung cancer (NSCLC), and discuss how the presence of brain or leptomeningeal metastases affects overall prognosis.
  • Differentiate among local therapy techniques for the management of brain metastases stemming from NSCLC, and determine which of these is most appropriate based on patient- and disease-specific factors (performance status, presence of an activating tumor mutation, number and location of lesions, et cetera).
  • Appraise the relative levels of CNS permeability with various EGFR tyrosine kinase inhibitors (TKIs), and discuss how this affects the efficacy of these agents against NSCLC with an EGFR mutation and brain metastases.
  • Review published research data documenting the safety and efficacy of the third-generation EGFR TKI osimertinib in the treatment of brain and leptomeningeal metastases, and discern how this information should be applied to current patient care.
  • Consider the uniqueness of leptomeningeal metastases as a clinical entity, and recall emerging data with promising diagnostic and therapeutic techniques in this setting.
  • Evaluate the activity of FDA-endorsed ALK inhibitors in patients with ALK-rearranged NSCLC and CNS metastases to optimize the selection and sequencing of targeted treatments.
  • Appreciate available clinical trial data with and recall the rationale for ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies for patients with NSCLC and brain metastases, and apply this information to provide appropriate counseling about protocol and nonresearch treatment options.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters
This activity is supported by an educational grant from AstraZeneca.

JW Marriott Desert Ridge Resort & Spa
5350 E Marriott Drive
Phoenix, AZ 85054
Hotel Phone: (480) 293-5000

Meeting Room
Grand Sonoran F (Level 1)

Directions
The JW Marriott Desert Ridge hotel is the host venue for the SNO 2019 Annual Meeting.

 

This activity is intended for neuro-oncologists, neurosurgeons, medical oncologists and other neuro-oncology practitioners involved in the treatment of lung cancer and CNS metastases.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.